Published Date: 15 Jul 2025
Progress toward universal access to safe, affordable surgical care is dangerously off track as at least 160 million patients each year are unable to receive surgery—with low- and middle-income countries (LMICs) bearing ...
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor
2.
A new FDA boxed warning; suicides rocking college campuses; more people getting flu shots than COVID vaccines.
3.
Universal screening approach achieves a comparable detection rate of lung cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.
1.
Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access
2.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
3.
What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Oropharyngeal Cancer in Relation to HPV Status
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Current Scenario of Cancer- Q&A Session to Close the Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation